Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins

In Ho Kim; Keith D. Combrink; Zhenkun Ma; Katrina Chapo; Dalai Yan; Paul Renick; Timothy W. Morris; Mark Pulse; Jerry W. Simecka; Charles Z. Ding

doi:10.1016/j.bmcl.2006.12.026

Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins

In Ho Kim, Keith D. Combrink, Zhenkun Ma, Katrina Chapo, Dalai Yan, Paul Renick, Timothy W. Morris, Mark Pulse, Jerry W. Simecka, Charles Z. Ding

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

A novel series of spirorifamycins was synthesized and their antibacterial activity evaluated both in vitro and in vivo. This new series of rifamycins shows excellent activity against Staphylococcus aureus that is equivalent to rifabutin. However, some compounds of the series exhibit lower MICs than rifabutin against rifampin-resistant strains of S. aureus. Further, compound 2e exhibits comparable efficacy in vivo in a murine model of S. aureus septicemia model following administration by either oral or parenteral dosing routes.

Original language	English
Pages (from-to)	1181-1184
Number of pages	4
Journal	Bioorganic and Medicinal Chemistry Letters
Volume	17
Issue number	5
DOIs	https://doi.org/10.1016/j.bmcl.2006.12.026
State	Published - 1 Mar 2007

Keywords

Ansamycin
Antibacterial
RNA polyerase inhibitors
Rifabutin
Rifampin-resistant
Rifamycin
Spirorifamycin
Staphylococcus aureus
Synthesis

Access to Document

10.1016/j.bmcl.2006.12.026

Cite this

@article{2f8548a02eea4039a4c5ce99db73a634,

title = "Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins",

abstract = "A novel series of spirorifamycins was synthesized and their antibacterial activity evaluated both in vitro and in vivo. This new series of rifamycins shows excellent activity against Staphylococcus aureus that is equivalent to rifabutin. However, some compounds of the series exhibit lower MICs than rifabutin against rifampin-resistant strains of S. aureus. Further, compound 2e exhibits comparable efficacy in vivo in a murine model of S. aureus septicemia model following administration by either oral or parenteral dosing routes.",

keywords = "Ansamycin, Antibacterial, RNA polyerase inhibitors, Rifabutin, Rifampin-resistant, Rifamycin, Spirorifamycin, Staphylococcus aureus, Synthesis",

author = "Kim, {In Ho} and Combrink, {Keith D.} and Zhenkun Ma and Katrina Chapo and Dalai Yan and Paul Renick and Morris, {Timothy W.} and Mark Pulse and Simecka, {Jerry W.} and Ding, {Charles Z.}",

year = "2007",

month = mar,

day = "1",

doi = "10.1016/j.bmcl.2006.12.026",

language = "English",

volume = "17",

pages = "1181--1184",

journal = "Bioorganic and Medicinal Chemistry Letters",

issn = "0960-894X",

publisher = "Elsevier Ltd",

number = "5",

}

TY - JOUR

T1 - Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins

AU - Kim, In Ho

AU - Combrink, Keith D.

AU - Ma, Zhenkun

AU - Chapo, Katrina

AU - Yan, Dalai

AU - Renick, Paul

AU - Morris, Timothy W.

AU - Pulse, Mark

AU - Simecka, Jerry W.

AU - Ding, Charles Z.

PY - 2007/3/1

Y1 - 2007/3/1

N2 - A novel series of spirorifamycins was synthesized and their antibacterial activity evaluated both in vitro and in vivo. This new series of rifamycins shows excellent activity against Staphylococcus aureus that is equivalent to rifabutin. However, some compounds of the series exhibit lower MICs than rifabutin against rifampin-resistant strains of S. aureus. Further, compound 2e exhibits comparable efficacy in vivo in a murine model of S. aureus septicemia model following administration by either oral or parenteral dosing routes.

AB - A novel series of spirorifamycins was synthesized and their antibacterial activity evaluated both in vitro and in vivo. This new series of rifamycins shows excellent activity against Staphylococcus aureus that is equivalent to rifabutin. However, some compounds of the series exhibit lower MICs than rifabutin against rifampin-resistant strains of S. aureus. Further, compound 2e exhibits comparable efficacy in vivo in a murine model of S. aureus septicemia model following administration by either oral or parenteral dosing routes.

KW - Ansamycin

KW - Antibacterial

KW - RNA polyerase inhibitors

KW - Rifabutin

KW - Rifampin-resistant

KW - Rifamycin

KW - Spirorifamycin

KW - Staphylococcus aureus

KW - Synthesis

UR - http://www.scopus.com/inward/record.url?scp=33846895011&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2006.12.026

DO - 10.1016/j.bmcl.2006.12.026

M3 - Article

C2 - 17189695

AN - SCOPUS:33846895011

SN - 0960-894X

VL - 17

SP - 1181

EP - 1184

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

IS - 5

ER -

Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this